Leif Kuse: Nudging the industry towards innovation with group purchasing for biotechs episode artwork

EPISODE · Jun 7, 2023 · 35 MIN

Leif Kuse: Nudging the industry towards innovation with group purchasing for biotechs

from Lab to Lives

Send us Fan MailThis week we speak to Leif Kuse, who is Lead Trailblazer of Drug Development Outsourcing Disruption and CEO PHARALL.We speak about group purchasing for biotechs in clinical trials. We start out by exploring how CRO contracting usually happens for biotechs, where clinical trials are typically outsourced to CROs. Biotech outsourcing is especially tricky, because in especially smaller companies, there may not be competencies to handle a sudden increase of people working for the company by adding a partner to the organization.   There are several models for collaborating with vendors - from a turnkey project, where you just “hand over the key” to a vendor, and wait for the results - to a close explorative collaboration, where the partner is basically a part of your organization. We discuss the difference in services and pricing that is on the table for big pharmaceutical companies and biotechs, exploring the dynamics of the market and collaboration models.There is no ideal CRO for a biotech - it all depends on what is needed, and how a collaboration can be established. Leif provides examples of great collaborations between CROs and biotech companies - where processes, culture and contracts all meshed. The patient stands to benefit from successful collaboration between sponsors and CROs. The trials can be executed more smoothly and drugs can make it to market more rapidly.  Lastly we discuss if the pharmaceutical value chain could be decentralized in general, with companies like PHARALL brokering different parts of the value chain into a coherent whole. Guest:Leif Kusehttps://www.linkedin.com/in/leif-kuse-32042411/PHARALLhttps://pharall.de/ Visit Labtolives.com Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/ Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/ Support the show________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn pageVisit www.labtolives.com HostsAlexander Booth aka the MedTech GuyDimitri Borisevich aka the start-up GuyIvanna Rosendal aka the R&D pharma Gal

Episode metadata supplied by the publisher feed · Published Jun 7, 2023

Embed this episode

Send us Fan Mail This week we speak to Leif Kuse, who is Lead Trailblazer of Drug Development Outsourcing Disruption and CEO PHARALL. We speak about group purchasing for biotechs in clinical trials. We start out by exploring how CRO contracting usually happens for biotechs, where clinical trials are typically outsourced to CROs. Biotech outsourcing is especially tricky, because in especially smaller companies, there may not be competencies to handle a sudden increase of people worki...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Leif Kuse: Nudging the industry towards innovation with group purchasing for biotechs

0:00 35:01

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Lab to Lives?

This episode is 35 minutes long.

When was this Lab to Lives episode published?

This episode was published on June 7, 2023.

Can I download this Lab to Lives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!